Raab & Moskowitz Asset Management LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Raab & Moskowitz Asset Management LLC has increased its holdings in Pfizer Inc. (NYSE:PFE) by 8.5% during the third quarter, as reported in their recent Form 13F filing with the SEC. After acquiring an additional 20,197 shares in the quarter, the fund now owns a total of 259,134 shares of the biopharmaceutical company. This investment accounts for approximately 1.9% of Raab & Moskowitz's total portfolio, making Pfizer their 12th largest position. At the close of the latest reporting period, Raab & Moskowitz's shares in Pfizer were valued at $7,499,000.

Recent Activity by Other Investors

In addition to Raab & Moskowitz, several other institutional investors and hedge funds have also adjusted their stakes in Pfizer. For example, Gladius Capital Management LP increased its stake by an impressive 102.8% during the third quarter, gaining ownership of 1,043 shares worth around $30,000 after acquiring 38,015 additional shares. Other notable trades include MFA Wealth Advisors LLC, Quarry LP, and Financial Connections Group Inc., each purchasing new stakes in Pfizer valued between approximately $29,000 to $34,000. Notably, Teachers Insurance & Annuity Association of America also bought a new position worth about $35,000. Overall, hedge funds and institutional investors collectively hold about 68.36% of the company's stock.

Analysts' Ratings and Price Targets

Recently, various analysts have set new ratings and price targets for Pfizer's shares. Wolfe Research initiated coverage with an "underperform" rating and a target price of $25.00. StockNews.com downgraded Pfizer's rating from "strong-buy" to "buy". In contrast, Evercore ISI upgraded the stock to "strong-buy". Citigroup assigned a "neutral" rating with a target price of $30.00, while Cantor Fitzgerald reaffirmed their "overweight" rating with a target price of $45.00. The overall consensus rating for Pfizer is "Moderate Buy,” with a target price of $32.92 based on MarketBeat data.

Pfizer's Price Performance

On the trading floor, Pfizer shares opened at $25.73 recently. The stock has experienced a 12-month low of $24.48 and a high of $31.54. Key financial metrics for the company include a current ratio of 1.00, a quick ratio of 0.73, and a debt-to-equity ratio of 0.63. With a market capitalization of $145.81 billion, Pfizer's price-to-earnings (P/E) ratio is reported at 34.77. Additionally, the company saw a significant year-over-year revenue increase by 31.2%, with the last quarter's revenue recorded at $17.70 billion, exceeding analyst expectations.

Pfizer Dividend Announcement

Moreover, Pfizer recently declared a quarterly dividend, which was paid out to shareholders on December 2. Shareholders of record received a dividend of $0.42 per share, translating to an annualized dividend of $1.68, resulting in a dividend yield of 6.53%. The company's dividend payout ratio currently stands at 227.03%.

Insider Transactions

In related news, Pfizer Director Scott Gottlieb bought 1,000 shares of the company on October 30 at an average price of $28.24 per share, totaling $28,240. Post-transaction, he now holds 10,000 shares, valued at approximately $282,400. This represents an increase of 11.11% in his stake, as disclosed in an SEC filing.

Company Overview

Pfizer Inc. specializes in discovering, developing, manufacturing, marketing, distributing, and selling biopharmaceutical products on a global scale. The company’s offerings span various therapeutic areas, including medications for cardiovascular health, migraine, infectious diseases, and treatments related to COVID-19, with notable brands such as Comirnaty and Paxlovid.

Pfizer, Stocks, Investment